PDF(Pubmed)
Abstract：
Introduction CD44, a multistructural and multifunctional transmembrane glycoprotein, is a promising cancer stem cell (CSC) marker that regulates the properties of CSCs, including self-renewal, tumor initiation, and metastasis, and confers resistance to chemotherapy and radiotherapy. The aim of the present study was to evaluate the gene and protein expression of CD44 and explore its prognostic value in head and neck squamous cell carcinoma (HNSCC). Methodology The present observational study employs computational tools for analysis. The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma dataset (520 primary HNSCC and 44 normal tissues) from the University of Alabama at Birmingham Cancer platform was used to study the association of CD44 mRNA transcript levels with various clinicopathological characteristics of HNSCC including age, gender, tumor grade, tumor stage, human papillomavirus (HPV) status, p53 mutation status, and overall survival. The CD44 protein expression in HNSCC and normal tissues was ascertained using the National Cancer Institute\'s Clinical Proteomic Tumor Analysis Consortium Head-and-Neck cancer dataset (108 primary HNSCC and 71 normal tissues). Results CD44 mRNA transcript and protein expression levels were significantly higher in HNSCC tissues than in normal tissues, and high CD44 expression was correlated with poor survival. CD44 was upregulated in Stage 1 and Grade 2 HNSCC compared with other stages and grades. Overexpression of CD44 was observed in HPV-negative and TP53-positive mutant status in HNSCC. Conclusion The pleiotropic roles of CD44 in tumorigenesis urge the need to explore its differential expression in HNSCC. The study concludes that CD44 can be a potential diagnostic and prognostic biomarker for HNSCC and offer new molecular targets for CD44-targeted therapy for cancer management.
摘要：
简介CD44，一种多结构和多功能跨膜糖蛋白，是一种有前途的癌症干细胞（CSC）标记，可调节CSC的特性，包括自我更新,肿瘤起始，和转移，并赋予对化疗和放疗的抵抗力。本研究的目的是评估CD44的基因和蛋白表达，并探讨其在头颈部鳞状细胞癌（HNSCC）中的预后价值。方法学本观察性研究采用计算工具进行分析。来自阿拉巴马大学伯明翰癌症平台的癌症基因组图谱头颈部鳞状细胞癌数据集（520个原发性HNSCC和44个正常组织）用于研究CD44mRNA转录水平与HNSCC的各种临床病理特征的关联，包括年龄，性别,肿瘤分级,肿瘤分期,人乳头瘤病毒（HPV）状态，p53突变状态,和总体生存率。使用美国国家癌症研究所的临床蛋白质组学肿瘤分析联盟头颈癌数据集(108个原发性HNSCC和71个正常组织)确定HNSCC和正常组织中的CD44蛋白表达。结果HNSCC组织中CD44mRNA转录和蛋白表达水平明显高于正常组织,高CD44表达与低生存率相关。与其他阶段和等级相比，CD44在1期和2级HNSCC中上调。在HNSCC中的HPV阴性和TP53阳性突变体状态中观察到CD44的过表达。结论CD44在肿瘤发生中的多效性作用，需要探索其在HNSCC中的差异表达。该研究得出结论，CD44可以成为HNSCC的潜在诊断和预后生物标志物，并为CD44靶向治疗癌症提供新的分子靶标。
